September 2016
Volume 57, Issue 12
Open Access
ARVO Annual Meeting Abstract  |   September 2016
Dexamethasone implant (Ozurdex©) intraocular pressure outcomes in the real-world
Author Affiliations & Notes
  • Javier Zarranz-Ventura
    Ophthalmology, Hospital Clinic Barcelona, Barcelona, Spain
    Medical Retina Service, Moorfields Eye Hospital, London, United Kingdom
  • Anna Sala-Puigdollers
    Ophthalmology, Hospital Clinic Barcelona, Barcelona, Spain
  • Daniel Velazquez Villoria
    Retina Service, Hospital Vall de Hebron, Barcelona, Spain
  • Marc Figueras-Roca
    Ophthalmology, Hospital Clinic Barcelona, Barcelona, Spain
  • Sergio Copete
    Retina Service, Hospital Vall de Hebron, Barcelona, Spain
  • Laura Natalia Distefano
    Retina Service, Hospital Vall de Hebron, Barcelona, Spain
  • Anna Boixadera Espax
    Retina Service, Hospital Vall de Hebron, Barcelona, Spain
  • Jose Garcia-Arumi
    Retina Service, Hospital Vall de Hebron, Barcelona, Spain
  • Alfredo Adan Civera
    Ophthalmology, Hospital Clinic Barcelona, Barcelona, Spain
  • Footnotes
    Commercial Relationships   Javier Zarranz-Ventura, Allergan (C), Bayer (S), Novartis (R), Topcon (S); Anna Sala-Puigdollers, None; Daniel Velazquez Villoria, None; Marc Figueras-Roca, None; Sergio Copete, None; Laura Distefano, None; Anna Boixadera Espax, None; Jose Garcia-Arumi, None; Alfredo Adan Civera, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science September 2016, Vol.57, 4153. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Javier Zarranz-Ventura, Anna Sala-Puigdollers, Daniel Velazquez Villoria, Marc Figueras-Roca, Sergio Copete, Laura Natalia Distefano, Anna Boixadera Espax, Jose Garcia-Arumi, Alfredo Adan Civera; Dexamethasone implant (Ozurdex©) intraocular pressure outcomes in the real-world. Invest. Ophthalmol. Vis. Sci. 2016;57(12):4153.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To investigate the real-world intraocular pressure (IOP) outcomes in a large cohort of eyes treated with the intravitreal dexamethasone implant (Ozurdex©).

Methods : Retrospective, two center, consecutive case series. 705 Ozurdex implants were injected in 438 eyes (403 patients) in two tertiary referral public centers (Hospital Clinic and Hospital Vall de Hebron, Barcelona, Spain). Clinical data collected included: Indication, injection dates, number of injections, previous treatments, and IOP prior to injection, 1-2 weeks and 6-8 weeks post-each injection. Proportion of glaucoma, ocular hypertension and eyes on hypotensive treatment at baseline, IOP change with repeat injections, cumulative incidence of IOP-lowering treatment need and proportion of eyes requiring glaucoma surgery were determined.

Results : Indications were diabetic macular edema in 47.3%, retinal vein occlusion in 28.6%, uveitis in 13% and others in 10.9%. At baseline, 8.8% of study eyes had glaucoma, 6.7% ocular hypertension and 16.9% were already on hypotensive topical treatment. IOP change at 6-8 weeks after first injection was +2.27±5.8, after second injection was +2.99±5.2 (p<0.001), after third injection was +3.39±5.8 (p<0.001) and after fourth injection was +4.55±5.3 (p<0.001). Once eyes on topical IOP-lowering treatment at baseline were excluded, the cumulative probability of starting topical treatment was 10.8% at 1 month, 18.5% at 2 months, 21.0% at 4 months, 23.7% at 6 months, 30.4% at 12 months, and 53.1% at 24 months. Glaucoma surgery was required in 0.91% of study eyes (4/438).

Conclusions : Repeated Ozurdex injections associate IOP changes of significantly higher magnitude, however the difference does not appear to be of clinical significance. The probability of starting IOP-lowering treatment increases with repeated injections. The percentage of treated eyes which require glaucoma surgery is very low (<1%) and consistent with the literature.

This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.

 

Box and whisker plot representing intraocular pressure change from baseline with each injection (6-8 weeks post-treatment). Significant differences were observed between each injection (p<0.001), although the range of variation appears clinically non-significant (range +2.27 to +4.55).

Box and whisker plot representing intraocular pressure change from baseline with each injection (6-8 weeks post-treatment). Significant differences were observed between each injection (p<0.001), although the range of variation appears clinically non-significant (range +2.27 to +4.55).

 

Kaplan Meier plot representing cumulative probability of IOP lowering treatment initiation after first injection, including only IOP lowering treatment-free eyes at baseline (83.1% of the study sample).

Kaplan Meier plot representing cumulative probability of IOP lowering treatment initiation after first injection, including only IOP lowering treatment-free eyes at baseline (83.1% of the study sample).

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×